




1 /27
Figure 1




2 /27
Figure 2




3 /27
Figure 3




4 /27
Figure 4




5 /27
Figure 5




6 /27
Figure 6




7 /27
Figure 7




8 /27
Figure 8




9/27
Figure 9




10 /27
Figure 10




11 /27
Figure 11



12 /27
Figure 12




13/27
Figure 13



14/27

Figure 14



15/27

Figure 15

CRC_P3 peptide (30 aa)


EpCam (15 aa) MAGE-A8 (15 aa)

YVDEKAPEFSMQGLK DEKVAELVRFLRKY

PolyPEP1018 vaccine antigens	Pre-clinical Immunogenicity		Clinical Immunogenicity
	Model population (n=433)	CRC cohort (n=37)	
TSP50	53%	62%	OBERTO-101 (n=10) 70%
EpCAM	69%	41%	90%
Survivin	36%	32%	70%
Cage	68%	81%	50%
SPAG9	28%	3%	40%
FBXO39	90%	100%	60%
MAGE-A8	18%	0%	60%
Any antigen	98%	100%	90%
Any 2 antigens	92%	92%	90%
Any 3 antigens	72%	65%	80%

*Lorincz et al. *Journal of Clinical Oncology* 37, 2019 (suppl; abstr e14298).

16/27
Figure 16A



Note: In the CAIRO3 trial the PFS1 was m8.5 month (95% CI 6.5-10.3)*

*CAIRO3 trial: Simkens et al. The Lancet 2015

17/27

Figure 16B







Figure 16C




18/27
Figure 17




19/27
Figure 18





20/27
Figure 19



21/27
Figure 20




22/27
Figure 21




23/27
Figure 22

Predicted Immunogenicity, PEPI = 12 : 10 CI95% [8, 12] (antigen specific T cell responses)
Detected Immunogenicity: 9 (20-mers) & 1 (9-mers) antigen (FSIP1) specific T cell responses
Positive T cell responses: >5 fold above control or >3 fold above control and >50 spots




Horizontal axes: Target antigens (expression rate in breast cancers)

25/27
Figure 24



26/27
Figure 25



27/27
Figure 26

